×
Ardelyx Total Liabilities 2013-2025 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ardelyx total liabilities from 2013 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Ardelyx Total Liabilities 2013-2025 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ardelyx total liabilities from 2013 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$76.6B
Zoetis (ZTS)
$69B
Takeda Pharmaceutical (TAK)
$46.7B
Daiichi Sankyo, - (DSNKY)
$41.7B
BeOne Medicines - (ONC)
$27.4B
Sandoz Group AG (SDZNY)
$24.6B
Summit Therapeutics (SMMT)
$18.6B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.2B
United Therapeutics (UTHR)
$13.3B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11B
IPSEN (IPSEY)
$10.3B
Stevanato Group S.p.A (STVN)
$7.6B
Corcept Therapeutics (CORT)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7B
Grifols, S.A (GRFS)
$6.7B
Ionis Pharmaceuticals (IONS)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.1B
Soleno Therapeutics (SLNO)
$4.1B
Crinetics Pharmaceuticals (CRNX)
$3B
Hypermarcas (HYPMY)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.4B
Centessa Pharmaceuticals (CNTA)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B
Ocular Therapeutix (OCUL)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.7B